| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17848404 | IVTH | 0.0000004 mg/L | 0.0000004 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000004 mg/L | 0.0000004 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000004 mg/L | 0.0000004 mg/L | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.0000004 mg/L | 0.0000004 mg/L | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| PMID:7925178 | IVTH | 0.00001 M | 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.